These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 16220029)

  • 1. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M
    Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus.
    Vaudaux P; Ferry T; Uçkay I; François P; Schrenzel J; Harbarth S; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3367-74. PubMed ID: 22833247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A;
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.
    Kobayashi Y
    J Infect Chemother; 2005 Oct; 11(5):259-61. PubMed ID: 16258825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
    Tabe Y; Nakamura A; Igari J
    J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
    Trakulsomboon S; Danchaivijitr S; Rongrungruang Y; Dhiraputra C; Susaemgrat W; Ito T; Hiramatsu K
    J Clin Microbiol; 2001 Feb; 39(2):591-5. PubMed ID: 11158112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model.
    Atahan E; Gul M; Ergun Y; Eroglu E
    Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):182-7. PubMed ID: 17481929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
    Bernard L; Vaudaux P; Rohner P; Huggler E; Armanet M; Pittet D; Lew DP; Schrenzel J
    J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-level resistance to glycopeptides amongst staphylococcus species: surveillance in a university hospital and evaluation of a vancomycin screening agar.
    Park YJ; Jun Park J; Lee SO; Oh EJ; Kee Kim B
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):155-9. PubMed ID: 11750170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.
    Uçkay I; Bernard L; Buzzi M; Harbarth S; François P; Huggler E; Ferry T; Schrenzel J; Renzoni A; Vaudaux P; Lew DP
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1258-64. PubMed ID: 22155824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.
    Vaudaux P; Huggler E; Bernard L; Ferry T; Renzoni A; Lew DP
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3861-70. PubMed ID: 20547791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus.
    Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y
    J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital.
    Nakipoglu Y; Derbentli S; Cagatay AA; Katranci H
    BMC Infect Dis; 2005 May; 5():31. PubMed ID: 15871748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of glycopeptide hetero-intermediate Staphylococcus aureus strains in Maltese hospitals.
    Borg MA; Zerafa R; Morrison D; Cuschieri P
    Clin Microbiol Infect; 2005 May; 11(5):405-7. PubMed ID: 15819869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
    Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.